INT295437

From wiki-pain
Revision as of 05:04, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.05
Pain Relevance 0.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CGA) small molecule metabolic process (CGA) extracellular region (CGA)
cellular nitrogen compound metabolic process (CGA) cell-cell signaling (CGA)
CGA (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 4 100.00 Very High Very High Very High
agonist 22 5.00 Very Low Very Low Very Low
antagonist 8 5.00 Very Low Very Low Very Low
Pain 6 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
pruritus 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Reprotox - General 2 16 52.24 Quite High
Ovarian Hyperstimulation Syndrome 22 6.48 Low Low
Polycystic Ovary Syndrome 18 5.00 Very Low Very Low Very Low
Anovulation 14 5.00 Very Low Very Low Very Low
Reprotox - General 1 12 5.00 Very Low Very Low Very Low
Reprotox - General 3 10 5.00 Very Low Very Low Very Low
Pain 6 5.00 Very Low Very Low Very Low
Endometriosis (extended) 6 5.00 Very Low Very Low Very Low
Abdominal Pain 4 5.00 Very Low Very Low Very Low
Vomiting 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lutropin alpha has a one compartment first-order process.42 Following subcutaneous administration of 150 IU lutropin alpha, a mean Cmax of 1.1 IU/L is reached after 6 hours (tmax).42 Lutropin alpha has a terminal half-life of about 18 hours and a bioavailability of 56% (following a single subcutaneous 10,000 IU dose).44

Manufacturing

Negative_regulation (bioavailability) of Protein_catabolism (administration) of lutropin alpha associated with bioavailability
1) Confidence 0.36 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819896 Disease Relevance 0 Pain Relevance 0.10
Lutropin alpha has a one compartment first-order process.42 Following subcutaneous administration of 150 IU lutropin alpha, a mean Cmax of 1.1 IU/L is reached after 6 hours (tmax).42 Lutropin alpha has a terminal half-life of about 18 hours and a bioavailability of 56% (following a single subcutaneous 10,000 IU dose).44

Manufacturing

Negative_regulation (bioavailability) of Protein_catabolism (administration) of Lutropin alpha associated with bioavailability
2) Confidence 0.36 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819896 Disease Relevance 0.05 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox